Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency.
净销售额达31.34亿美元，首次在上半年突破30亿美元大关，按固定汇率计算净销售额增长24.6%。
Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix.
国际市场和美国市场均实现广泛的两位数增长，所有产品类别亦普遍增长，主要受销量驱动，并辅以产品组合优化的积极影响。
Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology.
各产品类别表现均优于市场，按固定汇率计算，注射美学业务净销售额同比增长12.1%，皮肤学护肤业务增长16.4%，治疗性皮肤学业务增长67.9%。
Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ramp-up with approvals in 33 International markets, alongside continued investment in science-based innovation and medical education.
通过持续的地域扩张和差异化创新，彰显在皮肤学领域的领导地位，其中奈莫利珠单抗（Nemluvio®）实现净销售额4.33亿美元，Relfydess™（RelabotulinumtoxinA）持续放量，已在33个国际市场获批，同时公司持续加大对科学创新和医学教育的投入。
Core EBITDA margin expansion of 328 basis points at constant currency, ahead of initial expectations for the first half, with Core EBITDA reaching 802 million USD, up 42.8% year-on-year at constant currency, and a Core EBITDA margin of 25.6%.
核心EBITDA利润率按固定汇率计算扩大328个基点，超出上半年的初步预期，核心EBITDA达8.02亿美元，按固定汇率计算同比增长42.8%，核心EBITDA利润率为25.6%。
Core EPS grew to 2.34 USD, up 68.5% year-on-year, driven by strong Core EBITDA and reduced financing costs.
核心每股收益增至2.34美元，同比增长68.5%，得益于强劲的核心EBITDA和融资成本下降。
Raising 2026 full-year net sales guidance to 19-21% growth at constant currency (previously 17-20%) based on a strong trajectory, and confirming Core EBITDA margin of approximately 26% at constant currency.
